Last updated on August 2019

Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC


Brief description of study

The purpose of this study is to compare the clinical activity of durvalumab alone vs durvalumab in combination with novel agents. The overall study goal is early identification of novel durvalumab combinations that are more active than durvalumab alone in the treatment of patients with unresectable, Stage III NSCLC who have not progressed after cCRT.

Detailed Study Description

Study D9108C00001 (COAST) is a Phase 2, open-label, multicenter, randomized multidrug platform study assessing the efficacy and safety of durvalumab alone vs durvalumab in combination with novel agents in subjects with locally advanced, unresectable, Stage III non-small cell lung cancer (NSCLC).

Clinical Study Identifier: NCT03822351

Find a site near you

Start Over

Research Site

Orlando, FL United States
8.34miles
  Connect »